Catalog No.
KDJ53401
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human FGF23 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Burosumab in the sample competitively binds to the pre-coated protein with biotin-labeled Burosumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Burosumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
Burosumab
Applications
Used for the quantitative determination of Burosumab concentration in serum and plasma.
Sample type
Plasma, Serum
Range
31.25 - 2,000 ng/mL
Sensitivity
28.43 ng/mL
Precision
PRECISION
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
For research use only. Not for human or drug use.
